Mei pharma to consider strategic alternatives

San diego--(business wire)--mei pharma, inc. (nasdaq: meip) (the “company”) today announced that its board of directors has determined unanimously to begin evaluation of the company's strategic alternatives, including potential transactions as well as an orderly wind down of the company, if appropriate, in order to maximize the value of its assets for its stockholders. the company intends to evaluate and engage a financial advisor to assist in this process. in order to best preserve the company.
MEI Ratings Summary
MEI Quant Ranking